219 related articles for article (PubMed ID: 32944406)
1. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library.
Wu Y; Zhou L; Wang Z; Wang X; Zhang R; Zheng L; Kang T
Cancer Biol Med; 2020 Aug; 17(3):782-794. PubMed ID: 32944406
[No Abstract] [Full Text] [Related]
2. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
Toledo CM; Ding Y; Hoellerbauer P; Davis RJ; Basom R; Girard EJ; Lee E; Corrin P; Hart T; Bolouri H; Davison J; Zhang Q; Hardcastle J; Aronow BJ; Plaisier CL; Baliga NS; Moffat J; Lin Q; Li XN; Nam DH; Lee J; Pollard SM; Zhu J; Delrow JJ; Clurman BE; Olson JM; Paddison PJ
Cell Rep; 2015 Dec; 13(11):2425-2439. PubMed ID: 26673326
[TBL] [Abstract][Full Text] [Related]
3. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
4. High Expression of PKMYT1 Predicts Poor Prognosis and Aggravates the Progression of Osteosarcoma
Lu Y; Li P; Zhou Y; Zhang J
Curr Cancer Drug Targets; 2023; 23(6):496-504. PubMed ID: 36748214
[TBL] [Abstract][Full Text] [Related]
5. Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.
Feng Y; Sassi S; Shen JK; Yang X; Gao Y; Osaka E; Zhang J; Yang S; Yang C; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2015 Feb; 33(2):199-207. PubMed ID: 25348612
[TBL] [Abstract][Full Text] [Related]
6. Identification of LARS as an essential gene for osteosarcoma proliferation through large-Scale CRISPR-Cas9 screening database and experimental verification.
Chen W; Lin Y; Jiang M; Wang Q; Shu Q
J Transl Med; 2022 Aug; 20(1):355. PubMed ID: 35962451
[TBL] [Abstract][Full Text] [Related]
7. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
8. Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.
Kiessling MK; Schuierer S; Stertz S; Beibel M; Bergling S; Knehr J; Carbone W; de Vallière C; Tchinda J; Bouwmeester T; Seuwen K; Rogler G; Roma G
BMC Genomics; 2016 Sep; 17(1):723. PubMed ID: 27613601
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.
Liu T; Yan Z; Liu Y; Choy E; Hornicek FJ; Mankin H; Duan Z
Cell Physiol Biochem; 2018; 46(3):1218-1230. PubMed ID: 29672299
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 screening identified lethal genes enriched in necroptosis pathway and of prognosis significance in osteosarcoma.
Cheng L; Xiong W; Li S; Wang G; Zhou J; Li H
J Gene Med; 2023 Dec; 25(12):e3563. PubMed ID: 37421290
[TBL] [Abstract][Full Text] [Related]
11. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
[TBL] [Abstract][Full Text] [Related]
12. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
[TBL] [Abstract][Full Text] [Related]
13. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
Liao Y; Chen L; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
Oncotarget; 2017 May; 8(18):30276-30287. PubMed ID: 28415820
[TBL] [Abstract][Full Text] [Related]
14. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
15. Sprouty3, but Not Sprouty1, Expression Is Beneficial for the Malignant Potential of Osteosarcoma Cells.
Kamptner AZM; Mayer CE; Sutterlüty H
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769378
[TBL] [Abstract][Full Text] [Related]
16. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
[TBL] [Abstract][Full Text] [Related]
17. Microfluidic Cell Deformability Assay for Rapid and Efficient Kinase Screening with the CRISPR-Cas9 System.
Han X; Liu Z; Zhao L; Wang F; Yu Y; Yang J; Chen R; Qin L
Angew Chem Int Ed Engl; 2016 Jul; 55(30):8561-5. PubMed ID: 27258939
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.
Wang Q; Li J; Zhu J; Mao J; Duan C; Liang X; Zhu L; Zhu M; Zhang Z; Lin F; Guo R
Clin Transl Med; 2022 Jun; 12(6):e882. PubMed ID: 35692096
[TBL] [Abstract][Full Text] [Related]
19. miR-1285-3p is a potential prognostic marker in human osteosarcoma and functions as a tumor suppressor by targeting YAP1.
Hu XH; Dai J; Shang HL; Zhao ZX; Hao YD
Cancer Biomark; 2019; 25(1):1-10. PubMed ID: 31006663
[TBL] [Abstract][Full Text] [Related]
20. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells.
Hindriksen S; Bramer AJ; Truong MA; Vromans MJM; Post JB; Verlaan-Klink I; Snippert HJ; Lens SMA; Hadders MA
PLoS One; 2017; 12(6):e0179514. PubMed ID: 28640891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]